OSE Immunotherapeutics
Signal active
Organization
Contact Information
Overview
OSE Immunotherapeutics is a biotechnology company led by immunologists focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases, and transplantation. OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, FR104, and OSE-127 are among the company's products.
About
Industries
Biotechnology, Pharmaceutical, Medical, Medical Device, Oncology
Founded
2012
Employees
51-100
Headquarters locations
Europe
Social
N/A
Profile Resume
OSE Immunotherapeutics headquartered in Europe, operates in the Biotechnology, Pharmaceutical, Medical, Medical Device, Oncology sector. The company focuses on Biotechnology and has secured $8.6B in funding across 140 round(s). With a team of 51-100 employees, OSE Immunotherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - OSE Immunotherapeutics, raised $10.7M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
7
Investors
0
Lead Investors
0
Total Funding Amount
$61.7M
Details
0
OSE Immunotherapeutics has raised a total of $61.7M in funding over 0 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|
Investors
OSE Immunotherapeutics is funded by 11 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| OSE Immunotherapeutics | - | FUNDING ROUND - OSE Immunotherapeutics | 220.2K |
| Government of France | - | FUNDING ROUND - Government of France | 220.2K |
| OSE Immunotherapeutics | - | FUNDING ROUND - OSE Immunotherapeutics | 9.0M |
| France 2030 | - | FUNDING ROUND - France 2030 | 9.0M |
Recent Activity
There is no recent news or activity for this profile.